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Abstract. Mesenchymal stem cells (MSCs) contribute to 
the recovery of tissue injury, providing a paracrine support. 
Cell-derived extracellular vesicles (EVs), carrying membrane 
and cytoplasmatic constituents of the cell of origin, have 
been described as a fundamental mechanism of intercellular 
communication. We previously demonstrated that EVs derived 
from human MSCs accelerated recovery following acute 
kidney injury (AKI) in vivo. The aim of the present study was 
to investigate the biodistribution and the renal localization of 
EVs in AKI. For this purpose, two methods for EV labeling 
suitable for in vivo tracking with optical imaging (OI), were 
employed using near infrared (NIR) dye (DiD): i) labeled EVs 
were generated by MSCs pre-incubated with NIR dye and 
collected from cell supernatants; ii) purified EVs were directly 
labeled with NIR dye. EVs obtained with these two procedures 
were injected intravenously (i.v.) into mice with glycerol-
induced AKI and into healthy mice to compare the efficacy of 
the two labeling methods for in vivo detection of EVs at the site 
of damage. We found that the labeled EVs accumulated specifi-
cally in the kidneys of the mice with AKI compared with the 
healthy controls. After 5 h, the EVs were detectable in whole 
body images and in dissected kidneys by OI with both types of 
labeling procedures. The directly labeled EVs showed a higher 
and brighter fluorescence compared with the labeled EVs 
produced by cells. The signal generated by the directly labeled 
EVs was maintained in time, but provided a higher background 
than that of the labeled EVs produced by cells. The comparison 
of the two methods indicated that the latter displayed a greater 
specificity for the injured kidney.
Introduction
Cell-derived extracellular vesicles (EVs) contribute to inter-
cellular communication by transferring proteins, bioactive 
lipids and nucleic acids (1,2). EVs include exosomes released 
from multivesicular bodies and microvesicles shed from the 
cell surface. Both vesicle types contain membrane and cyto-
plasmic constituents of the cells of origin (3). In particular, 
EVs released from stem cells have been shown to transfer, 
following receptor-mediated incorporation, into target cells, 
mRNAs and miRNAs (4-8). Several studies have indicated 
that the regenerative potential of stem cell-based therapy is 
related to paracrine/endocrine mechanisms (9-11). EVs play 
a critical role in transferring regenerative signals from stem 
cells to the injured tissues (12-14).
Acute kidney injury (AKI) involves the rapid loss of kidney 
function consequent to a number of causes, which represents 
one of the main causes of morbidity and mortality in hospital-
ized patients. Moreover, AKI frequently evolves into chronic 
renal dysfunction (15). Bone marrow-derived mesenchymal 
stem cells (MSCs) have been found to improve recovery 
following AKI induced by toxic agents and ischemia/reper-
fusion injury (16-18). The observation that MSC-conditioned 
medium mimics the effect of cell treatment in AKI has 
suggested a role of MSC-derived factors in coordinating the 
repair process (11).
Previously, we found that EVs derived from human MSCs 
accelerated recovery following AKI in SCID mice in a manner 
comparable to the cells (13,19,20). Moreover, EVs, following 
incorporation into renal tubular epithelial cells, have been 
shown to transfer specific mRNA subsets and trigger a regen-
erative program (13).
To evaluate whether MSC-derived EVs may represent a 
potential therapeutic tool for AKI, it is essential to investi-
gate in vivo their biodistribution and recruitment within the 
injured kidneys. Optical imaging (OI) offers the potential for 
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a non-invasive study of different targets within the body of 
living animals. Recently, the OI technique has been improved 
with the possibility of visualizing a few labeled cells in vivo 
by using new dyes (21-24). Good candidate dyes to maximize 
the depth of tissue penetration and reduce the background are 
near-infrared (NIR) fluorophores (700-900 nm); the absorp-
tion coefficient of tissue is very low and light possesses a high 
potential for penetration (25-27).
The aim of this study was to use OI as a technique to visu-
alize in vivo the biodistribution and localization of EVs derived 
from MSCs in AKI within 24 h post-injection (glycerol). For 
this purpose, we compared two different labeling procedures, 
one based on direct EV labeling (DL-EV), and the other on the 
production of labeled EVs by donor cells pre-treated with the 
dye (LCD-EV).
Materials and methods
EV isolation. The MSCs were supplied by Lonza (Lonza, 
Basel, Switzerland) and cultured in the presence of MSC 
basal medium (MSCBM; Lonza). MSC-derived EVs were 
collected from the supernatant of MSCs cultured overnight 
in RPMI-1640 (Lonza) supplemented with 0.5% of BSA 
(Sigma-Aldrich, St. Louis, MO, USA). The cell supernatant 
was centrifuged twice at 3,000 x g for 20 min to remove cell 
debris and then ultracentrifuged at 100,000 x g (Beckman 
Coulter Optima L-90K ultracentrifuge; Beckman Coulter, 
Brea, CA, USA) for 1 h at 4˚C. EVs were stored in serum-free 
RPMI-1640 supplement with 1% DMSO at -80˚C. EV protein 
content was quantified by the Bradford method (Bio-Rad, 
Hercules, CA, USA).
Labeling procedure. Two labeling protocols were used: i) Cells 
were stained in suspension and incubated with 5 µM Vybrant 
Cell Tracers DiD [excitation (Ex), 640 nm; emission (Em), 
700 nm] or DiI (Ex, 530 nm; Em, 580 nm) (Molecular Probes, 
Eugene, OR, USA) solution without serum for 20 min at 37˚C. 
Cells were then washed in complete medium by centrifugation 
and cultivated for 24 h prior to supernatant collection. i) EVs 
were isolated by ultracentrifugation as previously described 
(LCD-EVs) (4,13). ii) EVs were directly labeled with 1 µM 
Vybrant Cell Tracers DiI or DiD during the ultracentrifugation 
procedure (DL-EVs) and then washed twice by ultracentrifu-
gation in 1X phosphate-buffered saline (PBS)  (28).
EV characterization. EVs labeled with the two methods were 
characterized by cytofluorimetric analysis using FITC- or 
PE-conjugated antibody against CD44, CD105, CD90 and 
α5-integrin. FITC or PE mouse non-immune isotypic IgG 
(Miltenyi Biotec, Bergisch Gladbach, Germany) were used as 
the controls. Briefly, EVs (10 µg) were incubated for 15 min 
at 4˚C with antibodies in 100 µl and then diluted in 300 µl 
and immediately acquired. FACS analysis was performed 
using a guava easyCyte Flow Cytometer (Millipore, Billerica, 
MA, USA) and analyzed with InCyte software, as previously 
described (29,30).
The size distribution of the LCD-EVs and DL-EVs was 
analyzed using a NanoSight LM10 instrument (NanoSight 
Ltd., Amesbury, UK) equipped with the nanoparticle tracking 
analyses (NTA) 2.0 analytic software.
In vitro uptake of EVs by human renal tubular epithelial cells. 
Human renal proximal tubular epitheial cells (PTECs) were 
labeled following the manufacturer's instructions with the 
CFSE green dye (Vybrant CFDA SE Cell Tracer kit; Molecular 
Probes). Cells were incubated for 5 h at 37˚C with 50 µg/ml 
DL-EVs or LCD-EVs and after washing the cells were fixed 
in 3.5% paraformaldehyde containing 2% sucrose. Confocal 
microscopy analysis was performed using a Zeiss LSM 5 Pascal 
model confocal microscope (Carl Zeiss, Oberkochen, Germany). 
Hoechst 33258 dye (Sigma-Aldrich) was added for nuclear 
staining.
Mouse model of AKI. Studies were conducted in accordance 
with the national guidelines and regulations and were approved 
by the Ethics Committee of the University of Torino. Male 
CD1 nude mice (6-8 weeks old) (Charles River Laboratories, 
Lyon, France), were fed for 1 week with a special diet (AIN 79; 
Mucedola, Settimo Milanese, Italy) to reduce tissue autofluo-
rescence. AKI was induced, as previously described (16), by 
an intramuscular injection of glycerol (7 ml/kg body weight 
of 50% glycerol solution) into the inferior hind limbs. At 
3 days post-injury, the mice were injected intravenously (i.v.) 
with 200 µg of DiD-labeled EVs. Sixteen nude mice with AKI 
were treated with LCD-EVs and were sacrificed after 5 h (n=9) 
and 24 h (n=7). Eleven nude mice with AKI were treated with 
DL-EVs and were sacrificed after 5 h (n=6) and 24 h (n=5). 
The same amount of LCD- and DL-EVs was i.v. injected in 12 
and 6 healthy mice, respectively. The animals were sacrificed 
after 5 h (LCD-EV, n=6; DL-EV, n=3) and 24 h (LCD-EV, 
n=6; DL-EV, n=3).
In vitro OI. In vitro experiments were performed using 
the IVIS 200 small animal imaging system (PerkinElmer, 
Waltham, MA, USA) using the Ex filter at 640 nm and the Em 
filter at 700 nm. Background fluorescence was measured and 
subtracted by setting up a background measurement (Ex filter, 
530 nm). EV samples were placed in a non-fluorescent black 
container and the fluorescence intensity of increasing concen-
trations of LCD-EVs and DL-EVs (15, 30, 50 and 100 µg) 
in the same volume was evaluated. Image analysis involved 
the designation of regions-of-interest (ROI) as the circular 
area of the well containing the EV concentrations to obtain 
the average intensity ± standard deviation (SD), as previously 
described (31).
In vivo OI. In vivo fluorescence imaging was performed with 
the same wavelength as described for in vitro acquisition. 
Identical illumination settings, such as exposure time (2 sec), 
binning factor (factor of 4), f/stop (set to 2) and 12 fields of view, 
were used for acquiring all images, and fluorescence Em was 
normalized to photons per second per centimeter squared per 
steradian (p/sec/cm2/sr). The color image represents the spatial 
distribution of fluorescence within the animal overlaid on black 
and white photographs of the mice, collected at the same time. 
Images were acquired and analyzed using Living Image 4.0 
software (PerkinElmer), as previously described (32).
The mice were anesthetized with 2.5% isoflurane (Merial, 
Lyon, France) and images were acquired in the prone and 
supine position after 15 min, 5 and 24 h post-EV injection. The 
mice with AKI and the healthy mice treated with PBS were 
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used as blank controls for the fluorescence signal of EVs in the 
AKI and healthy groups, respectively. The fluorescence signal 
was quantified in the kidney region and in the abdominal 
area, in ROI draw freehand. The relative mean fluorescence 
intensity of each ROI was obtained by subtracting the mean 
fluorescence intensity of the corresponding ROI on the blank 
mouse from the measured mean fluorescent intensity, as previ-
ously described (22,33). Data were expressed as the average 
radiance ± SD.
At the end of the experiments (5 or 24 h post-EV injec-
tion), the mice were sacrificed and dissected tissues (kidneys, 
spleen, liver and lungs) were imaged immediately. The mean 
fluorescence of each tissue sample was obtained by subtracting 
the fluorescence intensity of corresponding tissue from the 
blank mouse, as previously described (33).
Immunofluorescence. Mice were sacrificed at 5 and 24 h 
and confocal microscopy analysis (Leica TSC SP5 II) was 
performed on frozen sections for localization of DiD-labeled 
EVs in the kidneys. Hoechst 33258 dye (Sigma-Aldrich) 
was added for nuclear staining. Images were analyzed using 
ImageJ software.
Statistical analysis. The results are generally expressed as the 
means ± SD. Statistical analysis was performed by ANOVA 
with Dunnet's multi-comparison test or the Newman-Keuls 
multi-comparison or by the Student's t-test where appropriate. 
A p-value of <0.05 was considered to indicate a statistically 
significant difference.
Results
In vitro OI of labeled EVs. The OI of EVs obtained with the 
two following methods was compared: i) DL-EVs were labeled 
with DiD after their production and purification; ii) LCD-EVs 
were obtained by the supernatant of MSCs previously labeled 
with DiD and then cultured for 24 h prior to EV collection. 
OI images were acquired after EV dilution, ranging from 15 
to 100 µg of EV proteins, in 100 µl of PBS and the average 
intensity within the entire circle area of each well was calcu-
lated. The fluorescence signal correlated linearly with the 
EV concentration for both labeling methods. DL-EVs were 
brighter compared with LCD-EVs (Fig. 1).
In vitro characterization of fluorescent EVs and incorpora-
tion into renal epithelial tubular cells. EVs labeled with 
two methods showed the same phenotype as unlabeled EVs. 
Cytofluorimetric analyses showed their fluorescent signal in 
the NIR region (Fig. 2A and B) and the presence of several anti-
gens typically expressed by MSCs and by their EVs (13), such 
as CD44, CD105, CD90 and α5-integrin (Fig. 2C). Regarding 
size distribution analyzed with NanoSight, LCD-EVs showed 
a size range of 180±73 nm not significantly different from 
the size distribution of unlabeled EVs (145±57 nm). DL-EVs 
showed a size of 250±89 nm with a second peak of larger 
size probably due to some aggregations occurring during the 
labeling procedure (Fig. 3A).
To evaluate the ability of labeled EVs to be incorporated 
by PTECs, 50 µg/ml of EVs labeled with the red dye, DiI, 
following the same procedure described above, were added to 
the cells. DL-EVs and LCD-EVs were equally incorporated 
within PTECs, as observed by confocal microscopy after 5 h 
of incubation (Fig. 3B).
In vivo non-invasive OI visualization of EV biodistribution 
in AKI. The ability of labeled EVs to be visualized by OI on 
the whole body of live mice was assessed using an IVIS 200 
system in a model of AKI induced by an intramuscular glyc-
erol injection, as previously described (13). Three days after 
the glycerol injection, blood urea nitrogen (131±16 mg/dl) and 
creatinine (0.9±0.2 mg/dl) levels were significantly increased 
compared with the healthy controls (28±10 and 0.2±0.1 mg/dl, 
respectively) and were associated with diffuse tubular epithe-
lial injury, characterized by tubular hyaline casts, vacuolization 
and widespread necrosis of the proximal and distal tubular 
epithelium, loss of brush border and denudation of the basal 
membrane (data not shown). The 200 µg of DL-EVs or 
LCD-EVs was inoculated i.v. 3 days following the induction of 
AKI, when functional and morphological damage had reached 
its peak (13). Healthy mice were treated with the same amount 
of EVs in order to evaluate whether the accumulation of EVs 
was specific for the site of injury. Fig. 4 shows a fluorescent 
signal in the region of kidneys of AKI mice treated with 
LCD-EVs and DL-EVs and analyzed posterior after 15 min 
and 5 h. However, the intensity of fluorescence in the DL-EV-
treated mice with AKI was still present at 24 h after the i.v. 
injection and was significantly higher than the fluorescence 
signal generated by the kidneys of mice with AKI injected 
with LCD-EVs. In the healthy mice, we observed a fluorescent 
signal only in the mice treated with DL-EVs after 5 h in the 
left dorsal region that may correspond to spleen accumulation; 
however, the signal decreased rapidly and 24 h after the i.v. 
injection was not detectable (Fig. 4). Analyzing the signal 
Figure 1. In vitro fluorescence assay. (A) Representative in vitro fluorescence 
images of extracellular vesicle (EV) dilutions from 15 to 100 µg of protein in 
100 µl of phosphate-buffered saline (PBS). (B) Quantification of fluorescence 
signal calculated in the entire circle area of each well. Data are expressed as 
average radiance ± standard deviation (SD) of three different experiments. 
LCD-EV, labeled EVs produced by donor cells; DL-EV, directly labeled EVs.
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in the abdominal area, a higher fluorescence intensity was 
observed in the AKI groups compared with the healthy groups. 
Nevertheless, the DL-EV-treated mice with AKI displayed a 
major increase in fluorescence intensity in comparison with 
the LCD-EV-treated AKI group, possibly due to the accumu-
lation of EVs in the liver and spleen (Fig. 5).
Ex vivo OI analysis of dissected organs. For each experi-
mental group, the mice were sacrificed at 5 and 24 h after the 
EV injection and the fluorescent signal from freshly dissected 
tissues was quantified immediately by OI. The fluorescence 
intensity of the kidneys of mice with AKI treated with 
LCD-EVs and DL-EVs was significantly higher after 5 h 
Figure 3. Size analysis and incorporation by renal tubular epithelial cells. (A) Representative cell-derived extracellular vesicle (EV) sizes analyzed by measure-
ment with NanoSight. Three different preparation were analyzed with similar results. LCD-EVs maintain the same size distribution than the non-labeled EVs 
(180±73 nm). DL-EVs show a size of 250±89 nm with a second larger peak. (B) Representative micrographs of EV incorporation (5 h at 37˚C) in renal proximal 
tubular epithelial cells (PTECs). The EVs (red) produced with the two labeling procedures are equally incorporated by PTEC cells (green). Three experiments 
were performed with similar results. Nuclei were counterstained with DAPI (blue). Original magnification, x630. LCD-EV, labeled EVs produced by donor cells; 
DL-EV, directly labeled EVs.
Figure 2. Evaluation of fluorescence of labeled cell-derived extracellular vesicles (EVs) by a Guava cytofluorimeter. (A and B). Representative dot plots and 
histogram plots of the fluorescent signal of labeled EVs. (A) DL-EVs show a higher fluorescence compared with (B) LCD-EVs. (C) Representative cytofluorim-
eter analyses of DL-EVs showing the expression of CD44, CD105, CD90 and α5-integrin. EVs produced with the two staining procedures displayed analogous 
expression patterns of surface markers (data not shown). White filled histograms indicate the isotypic controls. Three different EV preparations were analyzed 
with similar results. LCD-EV, labeled EVs produced by donor cells; DL-EV, directly labeled EVs.
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compared with the kidneys of mice with AKI treated with 
PBS [AKI CTL (control)], as shown in Fig 6. Nevertheless, the 
increase in fluorescence was significantly maintained for 24 h 
following treatment in the DL-EV group, whereas it decreased 
in the LCD-EV group (Fig. 6A). No signal was detected in the 
kidneys of healthy mice treated with LCD-EVs and DL-EVs, 
suggesting a specific accumulation of EVs at the site of injury.
The fluorescence signal of DL-EVs was also detected in 
the spleen and particularly in the liver with high variability. 
The fluorescence signal of DL-EVs was of low intensity in 
the lungs of both the AKI and healthy groups. LCD-EVs were 
detectable only in the injured kidneys.
The presence of LCD-EVs and of DL-EVs within injured 
kidneys was confirmed by confocal analysis using the appro-
priate wavelength (Fig. 7). In the kidney sections derived from 
healthy mice, the presence of fluorescent EVs was almost absent.
Discussion
The results of the present study demonstrate that it is possible 
to analyze the biodistribution of EVs either by direct labeling 
or by the production of labeled EVs from MSCs. In particular, 
labeled MSC-derived EVs were found to localize within the 
injured kidneys.
Figure 4. In vivo cell-derived extracellular vesicle (EV) biodistribution in kidney region by optical imaging (OI). (A) Representative OI images, acquired in the 
posterior position following the induction of acute kidney injury (AKI) in mice and in healthy mice treated intravenously with 200 µg of LCD-EVs or DL-EVs 
or with an equal volume of phosphate-buffered saline (PBS) (CTL). (B) Quantification of fluorescence intensity in regions-of-interest (ROI) draw free hand in 
the region of kidneys, expressed as the average radiance ± standard deviation (SD). Sixteen AKI mice were treated with LCD-EVs, 11 AKI mice were treated 
with DL-EVs; healthy mice received the same amount of LCD- and DL-EVs (n=12 for LCD-EVs and n=6 for DL-EVs). ANOVA with Newman-Keuls multi-
comparison test was performed. *p<0.01 AKI DL-EV vs. all the other groups. LCD-EV, labeled EVs produced by donor cells; DL-EV, directly labeled EVs.
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The imaging of EVs in vivo may contribute to under-
standing the regenerative potential of EVs released from 
stem cells. Different approaches to visualize EVs have been 
proposed, exploiting fluorescent protein-based imaging, such 
as green fluorescent protein GFP (34), red fluorescent protein 
(RFP) (35), or the enzymatic activity of the luciferase enzyme 
which is secreted within exosomes (36). Nevertheless, the use 
of fluorescent proteins limits the visualization only to the EVs 
that possess the candidate proteins. Therefore, this technique 
cannot be applied to all type of vesicles. Since extracellular 
vesicles are a broad group, differing in content, size and surface 
markers (37,38) we used a technique that allows the labeling of 
EV lipid membranes.
The use of small-molecule fluorophores and, in particular, 
NIR molecules, is a powerful tool to track EVs for non-
invasive visualization. These dyes present strong and stable 
fluorescence in the EV membrane (28). NIR molecules exert 
a high tissue penetration in concomitance with a low back-
ground signal. These dyes have been employed for ex vivo EV 
detection (28). Since the possibility to trace these dyes in vivo 
has been shown for labeled cells and antibodies (33,39), in this 
study, we assessed the possibility to label EVs with DiD for 
EV tracking.
Previous publications addressing the biodistribution of 
EVs, have used the ex vivo detection of the dyes in dissected 
organs (28). Takahashi et al (36), using the luciferase activity 
Figure 5. In vivo cell-derived extracellular vesicle (EV) bio-distribution in abdominal area by optical imaging (OI). (A) Representative OI images, acquired the 
supine position following the induction of acute kidney injury (AKI) in mice and in healthy mice treated intravenously with 200 µg of LCD-EVs or DL-EVs 
or with an equal volume of phosphate-buffered saline (PBS) (CTL). (B) Quantification of fluorescence intensity in regions-of-interest (ROI) draw free hand in 
the abdominal area, expressed as the average radiance ± standard deviation (SD). Sixteen AKI mice were treated with LCD-EVs, 11 AKI mice were treated 
with DL-EVs; healthy mice received the same amount of LCD- and of DL-EVs (n=12 for LCD-EVs and n=6 for DL-EVs). ANOVA with Newman-Keuls multi-
comparison test was performed. *p<0.01 AKI DL-EV vs. all the other groups. LCD-EV, labeled EVs produced by donor cells; DL-EV, directly labeled EVs.
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of EVs, described the possibility to monitor their biodistribu-
tion within 4 h.
In this study, we compared the efficiency and sensibility 
of two labeling methods to visualize EVs in living animals. 
DiD-labeled EVs were obtained by direct labeling after their 
production or from the supernatant of MSCs previously incu-
bated with DiD. Labeled EVs were administered to a mouse 
model of AKI induced by a glycerol injection and compared 
Figure 6. Ex vivo optical imaging (OI) analysis of dissected organs. (A) Representative OI images of dissected organs of mice with acute kidney injury (AKI) 
and healthy mice treated with LCD- and DL-EVs sacrificed at 5 and 24 h after injection. (B) Fluorescence quantification of kidneys, expressed as the average 
radiance ± standard deviation (SD). ANOVA with Newman-Keuls multi-comparison test was performed. *p<0.05 AKI EVs vs. healthy EVs. (C) Fluorescence 
quantification, expressed as the average radiance ± SD, of lungs, liver and spleen. AKI mice treated with LCD-EVs sacrificed at 5 h (n=9) and at 24 h (n=7); 
AKI mice treated with DL-EVs sacrificed at 5 h (n=6) and at 24 h (n=5); healthy mice treated with LCD-EVs sacrificed at 5 h (n=6) and at 24 h (n=6); healthy 
mice treated with DL-EVs sacrificed at 5 h (n=3) and at 24 h (n=3). LCD-EV, labeled EVs produced by donor cells; DL-EV, directly labeled EVs.
Figure 7. Confocal microscopy of fluorescent cell-derived extracellular vesicles (EVs) in kidneys. Representative micrographs of kidney sections of mice with 
acute kidney injury (AKI) and healthy mice sacrificed at 5 and 24 h after EV injection (red). Nuclei were counterstained with Hoechst dye. Two kidney specimens 
were analyzed for each experimental point. Original magnification, x630. LCD-EV, labeled EVs produced by donor cells; DL-EV, directly labeled EVs.
GRANGE et al:  KIDNEY LOCALIZATION OF EXTRACELLULAR VESICLES1062
with healthy controls, to observe their biodistribution. EVs 
derived from human MSCs have been shown to accelerate 
the recovery of AKI in different mouse models (13,19,20). 
In the present study, we found that labeled EVs accumulated 
specifically in the kidneys of mice with AKI compared with 
healthy controls. After 5 h, the EVs were detectable in whole 
body images and in dissected kidneys by OI using both types 
of labeling procedure. However, the DL-EVs showed a higher 
and brighter fluorescence compared with the LCD-EVs. In 
the whole body, the signal generated by the DL-EVs was 
maintained for 24 h after the injection, whereas the signal of 
the LCD-EVs was detectable only in the dissected kidneys. 
Moreover, the liver and spleen of the mice treated with 
DL-EVs possessed a fluorescence signal due to a non-specific 
accumulation of EVs in the excretory organs. Comparing the 
two methods, the LCD-EVs showed a greater specificity due 
to their detection only in injured tissue, but the intensity of the 
fluorescence was lower than that of the DL-EVs. It is known 
that MSCs are recruited at the site of injury by receptor-
mediated interaction (16). MSC-derived EVs bear the same 
membrane receptors of MSCs; it is therefore possible that 
they may accumulate at the site of injury by exploiting the 
same mechanisms. In addition, the increased permeability in 
the injured kidney may account for the local accumulation of 
EVs in AKI.
In conclusion, both these labeling methods were found to 
be suitable for the in vivo detection of the renal localization 
of EVs. The localization of EVs in diseased, but not normal 
kidneys, may explain their beneficial effects on recovery 
following AKI.
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